Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea

Current Opinion in Investigational Drugs

Volumn 9, Issue 8, 2008, Pages 913-924

  Scheinfeld, N ^a   Biggers, K ^b  

^a St Luke's Roosevelt Hospital Center ^*  (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; COLESTYRAMINE; DIGOXIN; ERYTHROMYCIN; GATIFLOXACIN; GENTAMICIN; GLIBENCLAMIDE; GT 160246; GT 267004; GTS 160 246; IMIPENEM; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOLEVAMER; VANCOMYCIN; WARFARIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANTIBIOTIC ASSOCIATED COLITIS; BACTERIAL INFECTION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM DIFFICILLE ASSOCIATED DIARRHEA; COLITIS; CONSTIPATION; DEFECATION URGENCY; DIARRHEA; DRUG ABSORPTION; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG MEGADOSE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; FLATULENCE; HUMAN; HYPOKALEMIA; ISOTOPE LABELING; LOADING DRUG DOSE; LOOSE FECES; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; RECURRENT DISEASE; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CLOSTRIDIUM DIFFICILE; DRUG EVALUATION, PRECLINICAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; PATENTS AS TOPIC; POLYMERS;

EID: 48349106860     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. 352986 Positive results from phase I/II trial of C difficile vaccine. Peptide Therapeutics Group plc PRESS RELEASE 2000 January 20
2. 366517 GT160-246: A toxin-binding compound effective in the treatment of Clostridium difficile colitis in vivo. Kurtz CB, Cannon PE, Fitzpatrick R, Goddard PJ, Palace G, Klinger JD GASTROENTEROLOGY 2000 118 4 Suppl 2 Abs 2375
3. 367787 GelTex reports preclinical data on novel, new non-antibiotic therapy for 'Clostridium difficile'. GelTex Pharmaceuticals Inc PRESS RELEASE 2000 May 22
4. 379870 GelTex Pharmaceuticals reports completion of a phase I trial of a Clostridium difficile toxin binding polymer. GelTex Pharmaceuticals Inc PRESS RELEASE 2000 August 22
5. 384099 GT160-246: A toxin-binding polymer that prevents mortality in a hamster model of Clostridium difficile colitis relapse following treatment with metronidazole. Kurtz CB, Cannon EP, Fitzpatrick R, Barker RH, Klinger JD ICAAC 2000 40 Abs 2187
6. 452539 Our research - clinical trials. Genzyme Corp COMPANY WORLD WIDE WEB SITE 2002 May 21
7. 478976 GT160-246, a toxin-binding polymer for treatment of Clostridium difficile colitis. KuKurtz CB, Cannon EP, Brezzani A, Pitruzzello M, Dinardo C, Rinard E, Acheson DW, Fitzpatrick R, Kelly P, Shackett K, Papoulis AT et al ANTIMICROB AGENTS CHEMOTHER 2001 45 8 2340-2347 • A useful summary of the problems of Clostridium difficile-associated diarrhea and the potential of tolevamer as a new non-antibacterial therapy.
8. 481075 The binding of C difficile toxins to GT160-246, a novel anionic polymer that protects against antibiotic associated diarrhea. Braunlin WH, Xu Q, Hook P, Fitzpatrick R, Burrier R, Kurtz C BIOPHYS J 2001 80 1 Pt 2 Abs 315a
9. 538261 A phase 2 study of the toxin-binding polymer tolevamer in patients with C difficile-associated diarrhea. Louie T, Peppe J, Watt CK, Johnson DA, Mohammed RA, Dow G, Weiss K, Simon S, Davidson D GASTROENTEROLOGY 2004 126 4 Suppl 2 Abs T1785
10. 553852 Oscient Pharmaceuticals releases preliminary results from phase II ramoplanin trial for C difficile-associated diarrhea. Oscient Pharmaceuticals Corp PRESS RELEASE 2004 August 10
11. 587849 OSEL in-licenses therapeutic drug product from Japan. Osel Inc PRESS RELEASE 2005 March 02
12. 593139 Genzyme announces start of phase 3 study of novel, non-antibiotic therapy for C difficile-associated diarrhea. Genzyme Corp PRESS RELEASE 2005 April 04
13. 607542 Ilypsa website pipeline. Ilypsa Inc COMPANY WORLD WIDE WEB SITE 2005 December 06
14. 627852 Osel begins phase 2/3 clinical study for prevention of AAD. Osel Inc PRESS RELEASE 2005 October 11
15. 681600 NCT00106509: A study of GT267-004 versus vancomycin and GT267-004 versus metronidazole in patients with C difficile-associated diarrhea. CLINICALTRIALS.GOV 2006 May
16. 681613 NCT00196794: A study of GT267-004 versus vancomycin and GT267-004 versus metronidazole in patients with C difficile-associated diarrhea. CLINICALTRIALS.GOV 2005 November
17. 688651 Medarex and Massachusetts Biologic Laboratories announce commencement of phase II clinical trial of anti-C difficile antibody combination for the treatment of hospital-acquired diarrhea. Medarex Inc PRESS RELEASE 2006 September 06
18. 756593 Tolevamer, a novel toxin-binding polymer: Overview of preclinical pharmacology and physicochemical properties. Barker RH Jr, Dagher R, Davidson DM, Marquis JK ALIMENT PHARMACOL THER 2006 24 11-12 1525-1534
19. 767018 Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Braunlin W, Xu Q, Hook P, Fitzpatrick R, Klinger JD, Burrier R, Kurtz CB Biophys J 2004 87 1 534-539
20. 767020 Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Louie TJ, Peppe J, Watt CK, Johnson D, Mohammed R, Dow G, Weiss K, Simon S, John JF Jr, Garber G, Chasan-Taber S et al CLIN INFECT DIS 2006 43 4 411-420
21. 789247 Optimer Pharmaceuticals initiates second phase 3 trial of OPT-80 for CDAD. Optimer Pharmaceuticals Inc PRESS RELEASE 2007 May 01
22. 801363 NCT00466635: A study to assess the safety, tolerability, effectiveness and absorption of Exodif tablets in Clostridium difficile-associated diarrhea. CLINICALTRIALS.GOV 2007 July 18
23. 811314 Genzyme announces data from first phase III study of tolevamer in patients with C difficile-associated diarrhea. Genzyme Corp Pres Release 2007 July 06
24. 828323 Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD). Louie T, Gerson M, Grimard D, Johnson S, Poirier A, Weiss K, Peppe J, Donovan J, Davidson D ICAAC 2007 47 September 17 Poster K-425a
25. 910519 NCT00034294: A study of GT160-246 versus vancomycin in patients with Clostridium difficile-associated diarrhea. CLINICALTRIALS.GOV 2006 November 22
26. 910521 NCT00382304: A study of the absorption of GT267-004 in patients with Clostridium difficile-associated diarrhea. CLINICALTRIALS.GOV 2008
27. 910679 A randomised, double-blind, placebo-controlled, parallel-design trial of multiple doses of tolevamer in healthy male volunteers. Davidson D, Porzio A, Nealon P, Peppe J EUR CONGR CLIN MICROBIOL INFECT DIS 2005 15 Abs 1134_03_348
28. 916329 Clostridium difficile colitis. Kelly CP, Pothoulakis C, LaMont JT N Engl J Med 1994 330 4 257-262
29. 916330 Biological activities of toxins A and B of Clostridium difficile. Lyerly DM, Lockwood DE, Richardson SH, Wilkins TD Infect Immun 1982 35 3 1147-1150
30. 916438 Clostridium difficile infection in hospitals: A brewing storm. Valiquette L, Low DE, Pepin J, McGeer A CMAJ 2004 171 1 27-29 • The problems associated with Clostridium difficile infection and associated diarrhea are highlighted.
31. 916450 Hospitals battling outbreaks of C difficile. Eggertson L, Sibbald B. CMAJ 2004 171 1 19-21
32. 916451 Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. Pepin J, Valiquette L, Cossette B CMAJ 2005 173 9 1037-1042
33. 916453 Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC Lancet 2005 366 9491 1079-1084
34. 916454 Mechanisms and management of antibiotic-associated diarrhea. Hogenauer C, Hammer HF, Krejs GJ, Reisinger EC Clin Infect Dis 1998 27 4 702-710
35. 916503 Clostridium difficile-associated diarrhea in adults. Poutanen SM, Simor AE CMAJ 2004 171 1 51-57
36. 916506 Clostridium difficile toxins: Mechanism of action and role in disease. Voth DE, Ballard JD. Clin Microbiol Rev 2005 18 2 247-263
37. 916509 Clostridium difficile: Its disease and toxins. Lyerly DM, Krivan HC, Wilkins TD Clin Microbiol Rev 1988 1 1 1-18
38. 916514 Recurrence of symptoms in Clostridium difficile infection - relapse or reinfections? Wilcox MH, Fawley WN, Settle CD, Davidson A J Hosp Infect 1998 38 2 93-100
39. 916515 Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. Barbut F, Richard A, Hamandi K, Chomette V, Burghoffer B, Petit JC J Clin Microbiol 2000 38 6 2386-2388
40. 916516 Update on the changing epidemiology of Clostridium difficile-associated disease. McFarland LV Nat Clin Pract Gastroenterol Hepatol 2008 5 1 40-48
41. 916518 The burden of Clostridium difficile in surgical patients in the United States. Zerey M, Paton BL, Lincourt AE, Gersin KS, Kercher KW, Heniford BT Surg Infect (Larchmt) 2007 8 6 557-566
42. 916520 Vancomycin-induced elevation of liver enzyme levels. Cadle RM, Mansouri MD, Darouiche RO Ann Pharmacother 2006 40 6 1186-1189
43. 916521 Absorption of oral vancomycin - possible associated toxicity. Thompson CM Jr, Long SS, Gilligan PH, Prebis JW Int J Pediatr Nephrol 1983 4 1 1-4
44. 916522 Binary bacterial toxins: Biochemistry, biology, and applications of common Clostridium and Bacillus proteins. Barth H, Aktories K, Popoff MR, Stiles BG Microbiol Mol Biol Rev 2004 68 3 373-402
45. 916523 Aerial dissemination of Clostridium difficile spores. Roberts K, Smith CF, Snelling AM, Kerr KG, Banfield KR, Sleigh PA, Beggs CB BMC Infect Dis 2008 8 7
46. 916524 Hypervirulent strains of Clostridium difficile. Cookson B POSTGRAD Med J 2007 83 979 291-295
47. 916526 Increased sporulation rate of epidemic Clostridium difficile type 027/NAP1. Akerlund T, Persson I, Unemo M, Norén T, Svenungsson B, Wullt M, Burman LG J Clin Microbiol 2008 46 4 1530-1533
48. 916527 Treatment of Clostridium difficile infection. Gerding DN, Muto CA, Owens RC Jr Clin Infect Dis 2008 46 Suppl 1 S32-S42
49. 916530 Rho protein regulates tight junctions and perijunctional actin organization in polarized epithelia. Nusrat A, Giry M, Turner JR, Colgan SP, Parkos CA, Carnes D, Lemichez E, Boquet P, Madara JL Proc Natl Acad Sci USA 1995 92 23 10629-10633
50. 916531 Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins. Nusrat A, von Eichel-Streiber C, Turner JR, Verkade P, Madara JL, Parkos CA Infect Immun 2001 69 3 1329-1336
51. 916532 Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. Hecht G, Pothoulakis C, LaMont JT, Madara JL J Clin Invest 1988 82 5 1516-1524
52. 916537 A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: A randomized phase I trial. Peppe J, Porzio A, Davidson DM Br J Clin Pharmacol 2008 66 1 102-109.
53. 916539 Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C difficile infections in Europe. Spigaglia P, Barbanti F, Mastrantonio P, Brazier JS, Barbut F, Delmee M, Kuijper E, Poxton IR, European Study Group on Clostridium difficile (ESGCD) J Med Microbiol 2008 57 784-789
54. 916541 Risk factors for Clostridium difficile infection. Bignardi GE J Hosp Infect 1998 40 1 1-15
55. 916542 Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease? Dhalla IA, Mamdani MM, Simor AE, Kopp A, Rochon PA, Juurlink DN Antimicrob Agents Chemother 2006 50 9 3216-3219
56. 916545 Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: A cohort study during an epidemic in Quebec. Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M et al Clin Infect Dis 2005 41 9 1254-1260
57. 916547 Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Zilberberg MD, Shorr AF, Kollef MH. Emerg Infect Dis 2008 14 6 929-931
58. 916548 Pharmacokinetics and drug dosage adjustment to renal impairment. Keller F, Giehl M, Frankewitsch T, Zellner D Nephrol Dial Transplant 1995 10 9 1516-1520
59. 917248 Emergence of an epidemic strain of Clostridium difficile in the United States 2001-4: Potential role for virulence factors and antimicrobial resistance traits. McDonald LC, Killgore GE, Thompson A, Johnson S, Gerding DN; C difficile Investigation Team ANNU MEET INFECT DIS SOC AM 2004 42 Abs LB-2
60. 917249 Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile. Hinkson PL, Dinardo C, DeCiero D, Klinger JD, Barker RH Jr ANTIMICROB AGENTS CHEMOTHER 2008 52 6 2190-2195
61. 917264 A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB CLIN INFECT DIS 2007 45 3 302-307
62. 917269 Bench-to-bedside review: Clostridium difficile colitis. Gould CV, McDonald LC CRIT CARE 2008 12 1 203
63. 918806 Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea. Bouza E, Dryden M, Mohammed R, Peppe J, Chasan-Taber S, Donovan J, Davidson D, Short G, Polymer Alternative for CDAD Treatment (PACT) Investigators ECCMID 2008 18 Abs O464
64. 918838 WO-2004009100: Poly (potassium and sodium styrene sulfonate), its manufacture and its uses. Mhaskar SV, Bhagat HR, Kurtz CI, Katti SS, Chancellor-Adams TG, Chorghade MS WORLD PATENT 2004 January 29
65. 919924 Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates. Hoogkamp-Korstanje JAA, Roelofs-Willemse J J ANTIMICROB CHEMOTHER 2000 45 1 31-39
66. 920067 Binary toxin production in Clostridium difficile is regulated by CdtR, a LytTR family response regulator. Carter GP, Lyras D, Allen DL, Mackin KE, Howarth PM, O'Connor JR, Rood JI J BACTERIOL 2007 189 20 7290-7301
67. 920194 WO-2008030512: Polystyrene sulfonate polymer tablets, their preparation and use. Ho C, Chawla J, Bhagat HR WORLD PATENT 2008 March 13
68. 920608 WO-00069428: Anionic polymers as toxin binders and antibacterial agents. Kurtz C, Fitzpatrick R WORLD PATENT 2000 November 23